Download video

Dr. Rugo on Takeaways From the IMpassion130 Trial in TNBC

97 views

OncLive

4 years ago

Dr. Rugo on Takeaways From the IMpassion130 Trial in TNBC

Dr. Rugo on Takeaways From the IMpassion130 Trial in TNBC

Dr. Rugo on Takeaways From the IMpassion130 Trial in TNBC
1:39
Dr. Rugo on Takeaways From the IMpassion130 Trial in TNBC
by OncLive
Dr. Rugo on the Results of the KEYNOTE-522 Trial in TNBC
1:43
Dr. Rugo on the Results of the KEYNOTE-522 Trial in TNBC
by OncLive
Case 3: Results of the IMpassion130 Trial in Metastatic Breast Cancer
6:33
Case 3: Results of the IMpassion130 Trial in Metastatic Breast Cancer
by Targeted Oncology
IMpassion130 Trial Data on PD-L1+ Tumors in TNBC
6:56
IMpassion130 Trial Data on PD-L1+ Tumors in TNBC
by OncLive
Dr. Rugo on Recent Updates With Immunotherapy in TNBC
1:52
Dr. Rugo on Recent Updates With Immunotherapy in TNBC
by OncLive
IMpassion130 Trial Data on PD-L1+ Tumors in TNBC
6:54
IMpassion130 Trial Data on PD-L1+ Tumors in TNBC
by AJMCtv
Hope Rugo, MD, offers key takeaways for physicians regarding KEYNOTE-355
1:42
Hope Rugo, MD, offers key takeaways for physicians regarding KEYNOTE-355
by OBRoncology
Chemoimmunotherapy in TNBC: The IMpassion130 Trial
8:42
Chemoimmunotherapy in TNBC: The IMpassion130 Trial
by OncLive
The IMpassion130 Trial in Metastatic Triple-Negative Breast Cancer
1:16
The IMpassion130 Trial in Metastatic Triple-Negative Breast Cancer
by Targeted Oncology
IMpassion130: immunotherapy for TNBC
2:30
IMpassion130: immunotherapy for TNBC
by VJOncology
TNBC: Updated Efficacy Results From IMpassion130
4:47
TNBC: Updated Efficacy Results From IMpassion130
by OncLive
Dr. Rugo Discusses Immunotherapy in TNBC
1:50
Dr. Rugo Discusses Immunotherapy in TNBC
by OncLive
KEYNOTE-522 Demonstrates Potential for Immunotherapy in Triple-Negative Breast Cancer
0:53
KEYNOTE-522 Demonstrates Potential for Immunotherapy in Triple-Negative Breast Cancer
by Targeted Oncology
IMpassion130 Trial: OS Updates in Metastatic TNBC
7:19
IMpassion130 Trial: OS Updates in Metastatic TNBC
by OncLive
Hope Rugo, MD, considers the incidence of TNBC and what makes this disease so difficult to treat
2:02
Hope Rugo, MD, considers the incidence of TNBC and what makes this disease so difficult to treat
by OBRoncology
Applying IMpassion130 Data to TNBC Management
2:33
Applying IMpassion130 Data to TNBC Management
by OncLive
Immunotherapy for TNBC: IMpassion130 \& KEYNOTE-355
4:11
Immunotherapy for TNBC: IMpassion130 \& KEYNOTE-355
by VJOncology
I-O in TNBC: IMpassion130 Trial Design and Results
4:33
I-O in TNBC: IMpassion130 Trial Design and Results
by OncLive
Hope Rugo, MD, provides perspective on the clinical progress of CDK 4\/6 inhibitors in breast cancer
4:50
Hope Rugo, MD, provides perspective on the clinical progress of CDK 4\/6 inhibitors in breast cancer
by OBRoncology
Results from the IMpassion130 trial for triple-negative breast cancer
4:53
Results from the IMpassion130 trial for triple-negative breast cancer
by ecancer